Acer Therapeutics Discusses Developing COVID-19 Clinical Program, Next Steps with the FDA and Vision for 2020 in New Video Interview on SNN Network -…

Posted: Published on May 25th, 2020

This post was added by Alex Diaz-Granados

LOS ANGELES, CA / ACCESSWIRE / May 21, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source, today published a new Video Interview with Chris Schelling, CEO and Founder of Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, according to the company's website (see here: http://www.acertx.com).

Click the following link to watch the Video Interview:

Acer Therapeutics Inc. - Discusses Reformulated Assets to Develop COVID-19 Clinical Program, Next Steps with the FDA and Vision for 2020

You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Acer Therapeutics Inc.

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of induced Vasomotor Symptoms (iVMS) where Hormone Replacement Therapy (HRT) is likely contraindicated. Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit http://www.acertx.com.

About SNN Network

SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.

Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym

CONTACT: SNN Network info@snnwire.com

SOURCE: Stock News Now

View source version on accesswire.com: https://www.accesswire.com/590830/Acer-Therapeutics-Discusses-Developing-COVID-19-Clinical-Program-Next-Steps-with-the-FDA-and-Vision-for-2020-in-New-Video-Interview-on-SNN-Network

View post:
Acer Therapeutics Discusses Developing COVID-19 Clinical Program, Next Steps with the FDA and Vision for 2020 in New Video Interview on SNN Network -...

Related Posts
This entry was posted in Hormone Replacement Therapy. Bookmark the permalink.

Comments are closed.